BA3071

Phase 2Biologic

BBioAtla, Inc.

BA3071 is one of 48 biologic programs targeting Patients With Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Solid TumorsActive, not recruiting

Patients With Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

68 competitors in Patients With Solid Tumors

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

13 2

Faslodex

FFresenius Kabi USA, LLC

Phase 3

2 3

Keytruda

Merck & Co.

Phase 2

6 4

Avastin

Roche

Phase 2

6 5

Opdivo

Bristol-Myers Squibb

Phase 2

5 6

Imfinzi

AstraZeneca

Phase 2

3 7

Eloxatin

Teva

Phase 2

2 8

Lynparza

AstraZeneca

Phase 2

1 9

Mektovi

Pfizer

Phase 2

1 10

Pemazyre

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patients With Solid Tumors1 trial

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Active, not recruiting·BBioAtla, Inc.·Phase 1/2·NCT05180799·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BA3071. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BA3071 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BA3071. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioAtla, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBioAtla, Inc.

BA3071

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News